Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Operations (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Cash from Operations for 6 consecutive years, with 20043000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 914.84% year-over-year to 20043000.0, compared with a TTM value of 28626000.0 through Dec 2025, up 177.41%, and an annual FY2025 reading of 28626000.0, up 177.41% over the prior year.
  • Cash from Operations was 20043000.0 for Q4 2025 at Xeris Biopharma Holdings, up from 18432000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 20043000.0 in Q4 2025 and bottomed at 48409000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 12690200.0, with a median of 15364500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 166.32% in 2021, then skyrocketed 914.84% in 2025.
  • Year by year, Cash from Operations stood at 28946000.0 in 2021, then soared by 44.31% to 16119000.0 in 2022, then soared by 146.35% to 7471000.0 in 2023, then plummeted by 73.56% to 1975000.0 in 2024, then surged by 914.84% to 20043000.0 in 2025.
  • Business Quant data shows Cash from Operations for XERS at 20043000.0 in Q4 2025, 18432000.0 in Q3 2025, and 182000.0 in Q2 2025.